Trial Profile
An non randomized, open label study to evaluate Safety and Efficacy of Morotocog Alfa (AF-CC) in Previously Untreated Patients Aged <6 Years in Usual Care Settings
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2017
Price :
$35
*
At a glance
- Drugs Moroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- 26 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology